Clinical trial of investigation of add-on of Probiotics to standard treatment on symptoms of patients with first episode schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120603009934N2

Enrollment

Registered

2019-03-17

Start date

2019-03-06

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: : Individuals in intervention group will receive a probiotic capsule on lunch during the day for 12 weeks. Probiotics is a Femilact capsule that produced by the Zis

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with schizophrenia, Age: 18 to 60 years First episode schizophrenia Received a fixed dose of an anti psychotic drug Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy Serious neurological diseases Serious medical illness (Cardiovascular disease, Nephrology disease) The use of any drug for weight loss The use of substances drug or alcohol in the 3 last months, Received antibiotics in the last two weeks low IQ (less than 70)

Design outcomes

Primary

Measure	Time frame
Symptoms of patients. Timepoint: In weeks 4, 8, 12. Method of measurement: Brief Psychiatric Rating Scale (BPRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Robabeh Soleimani

Rasht University of Medical Sciences

rsoleimani@yahoo.com+98 13 3366 6268

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026